Vanda Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ US9216591084

Introduction

This page provides a comprehensive analysis of the known insider trading history of Howard H Pien. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Howard H Pien has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IDRA / Idera Pharmaceuticals, Inc. Director 45,457
US:JUNO / Juno Therapeutics, Inc. Director 0
US:IMGN / ImmunoGen, Inc. Director 78,298
US:SAGE / Sage Therapeutics, Inc. Director 13,922
US:VNDA / Vanda Pharmaceuticals Inc. Director 15,000
US:VPHM / Shire Viropharma Inc Director 0
US:TLON / Talon Therapeutics, Inc. Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Howard H Pien. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases VNDA / Vanda Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in VNDA / Vanda Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VNDA / Vanda Pharmaceuticals Inc. Insider Trades
Insider Sales VNDA / Vanda Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in VNDA / Vanda Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VNDA / Vanda Pharmaceuticals Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Howard H Pien as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2020-10-05 2020-10-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 5,583 45,457 14.00 2.25 12,562 102,278
2020-07-02 2020-07-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 7,018 39,874 21.36 1.79 12,562 71,374
2020-05-19 2020-05-12 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 11,500 11,500
2020-04-03 2020-04-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 9,666 32,856 41.68 1.28 12,372 42,056
2020-01-06 2020-01-02 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 6,790 23,190 41.40 1.85 12,562 42,902
2019-10-02 2019-10-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 4,610 16,400 39.10 2.67 12,309 43,788
2019-07-02 2019-07-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 4,469 11,790 61.04 2.61 11,664 30,772
2019-06-06 2019-06-04 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 11,500 11,500
2019-04-02 2019-04-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 4,392 7,321 149.95 2.59 11,375 18,961
2019-01-03 2019-01-02 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 2,929 2,929 3.52 10,310 10,310
2018-09-20 2018-09-18 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 23,000 23,000
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -12,000 0 -100.00 63.71 -764,520
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -12,000 0 -100.00 44.60 -535,200
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -12,000 0 -100.00 27.00 -324,000
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -5,050 0 -100.00 87.00 -439,350
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
U - Other -111,587 5,050 -95.67 87.00 -9,708,069 439,350
2018-03-07 2018-02-13 4 JUNO Juno Therapeutics, Inc.
Common Stock
G - Gift -1,162 116,637 -0.99
2018-03-07 2018-02-09 4 JUNO Juno Therapeutics, Inc.
Common Stock
G - Gift -12,251 117,799 -9.42
2018-01-09 2018-01-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 417 130,050 0.32
2018-01-09 2017-12-22 4 JUNO Juno Therapeutics, Inc.
Common Stock
G - Gift -25,000 129,633 -16.17
2018-01-03 2017-12-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,033 78,298 1.34
2017-10-06 2017-10-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 447 154,633 0.29
2017-10-03 2017-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 882 77,265 1.15
2017-07-07 2017-07-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 640 154,186 0.42
2017-07-03 2017-06-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 949 76,383 1.26
2017-06-19 2017-06-16 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 12,000 12,000
2017-06-15 2017-06-13 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 10,000 10,000 4.64 46,400 46,400
2017-06-15 2017-06-13 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 3,000 75,434 4.14
2017-04-06 2017-04-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 865 153,546 0.57
2017-04-04 2017-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,744 72,434 2.47
2017-01-09 2017-01-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 995 152,681 0.66
2017-01-03 2017-01-03 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 6,617 70,690 10.33
2016-12-13 2016-12-09 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 5,000 5,000 1.84 9,200 9,200
2016-12-13 2016-12-09 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,500 64,073 2.40
2016-10-17 2016-10-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 675 151,686 0.45
2016-10-03 2016-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 5,037 62,573 8.75
2016-07-06 2016-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 4,383 57,536 8.25
2016-07-05 2016-07-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 505 151,011 0.34
2016-06-24 2016-06-22 4 SAGE Sage Therapeutics, Inc.
Stock Options (Right to buy)
A - Award 13,922 13,922 28.35 394,689 394,689
2016-06-21 2016-06-17 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 12,000 12,000
2016-04-07 2016-04-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 506 150,506 0.34
2016-04-04 2016-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,584 53,153 3.07
2016-01-04 2015-12-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 994 51,569 1.97
2015-11-12 2015-11-10 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 10,000 10,000 13.07 130,700 130,700
2015-11-12 2015-11-10 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 3,000 50,575 6.31
2015-10-01 2015-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,406 47,575 3.05
2015-07-01 2015-06-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 938 46,169 2.07
2015-06-22 2015-06-18 4 VNDA Vanda Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2015-06-16 2015-06-12 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 12,000 12,000
2015-05-29 2015-05-28 4 SAGE Sage Therapeutics, Inc.
Stock Options (Right to buy)
A - Award 13,922 13,922 73.13 1,018,116 1,018,116
2015-04-02 2015-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,508 45,231 3.45
2015-01-02 2014-12-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 2,213 43,723 5.33
2014-12-23 2014-12-23 4 JUNO Juno Therapeutics, Inc.
Series A-2 Preferred Stock
C - Conversion -75,000 0 -100.00
2014-12-23 2014-12-23 4 JUNO Juno Therapeutics, Inc.
Common Stock
C - Conversion 75,000 150,000 100.00
2014-12-18 3 JUNO Juno Therapeutics, Inc.
Common Stock
150,000
2014-12-18 3 JUNO Juno Therapeutics, Inc.
Common Stock
150,000
2014-11-12 2014-11-11 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 10,000 10,000 10.10 101,000 101,000
2014-11-12 2014-11-11 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 3,000 41,510 7.79
2014-10-01 2014-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,274 38,510 3.42
2014-07-02 2014-06-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 1,139 1,139
2014-06-04 2014-05-22 4 VNDA Vanda Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2014-04-01 2014-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 904 904
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Restricted Stock Units
D - Sale to Issuer -4,500 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -25,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -7,500 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Common Stock
U - Other -9,000 0 -100.00 50.00 -450,000
2014-01-02 2013-12-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 840 840
2013-11-13 2013-11-12 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 10,000 10,000 14.70 147,000 147,000
2013-11-13 2013-11-12 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 3,000 3,000
2013-10-02 2013-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 646 646
2013-07-18 2013-07-17 4 TLON Talon Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -35,000 0 -100.00
2013-07-18 2013-07-17 4 TLON Talon Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00
2013-07-01 2013-06-28 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 663 663
2013-06-24 2013-06-20 4 VNDA Vanda Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2013-04-02 2013-03-29 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 684 684
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Restricted Stock Units
A - Award 4,500 4,500
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Common Stock
A - Award 4,500 9,000 100.00
2013-01-29 2013-01-25 4 TLON Talon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 35,000 35,000
2013-01-02 2012-12-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 862 862
2012-11-15 2012-11-13 4 IMGN IMMUNOGEN INC
Stock option (right to buy)
A - Award 4,645 4,645 11.42 53,046 53,046
2012-11-15 2012-11-13 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 2,626 2,626
2012-10-01 2012-09-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 753 753
2012-07-02 2012-06-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 657 657
2012-06-18 2012-06-14 4 VNDA Vanda Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2012-04-24 2012-04-20 4 TLON Talon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2012-04-03 2012-03-31 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 764 764
2012-02-28 2012-02-24 4 VPHM VIROPHARMA INC
Restricted Stock Units
A - Award 4,500 4,500
2012-02-28 2012-02-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
A - Award 15,000 15,000
2012-02-28 2012-02-21 4 VPHM VIROPHARMA INC
Common Stock
A - Award 4,500 4,500
2012-01-03 2011-12-30 4 IMGN IMMUNOGEN INC
Deferred Share Unit
A - Award 913 913
2009-11-13 3 IMGN IMMUNOGEN INC
Common Stock
2,168
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)